NewAmsterdam Pharma Co N.V. (NAMS) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 37 days, typically, give or take 8 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q2 FY2026Wed, Aug 5, 2026before open 36 8-K
Q1 FY2026Thu, May 7, 2026before open 37 8-K
Q4 FY2025Wed, Feb 18, 2026before open 49 8-K
Q3 FY2025Wed, Nov 5, 2025before open 36 8-K
Q2 FY2025Wed, Aug 6, 2025before open 37 8-K
Q1 FY2025Thu, May 8, 2025before open 38 8-K
Q4 FY2024Wed, Feb 26, 2025before open 57 8-K
Q3 FY2024Wed, Nov 6, 2024before open 37 8-K

What they guided beta

Q2 FY2026 "– PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topline data from RUBENS Phase 3 expected by year-end 2026 – – $678.3 million in cash, cash equivalents and marketable securities at June 30, 2026 –" exhibit
Q2 FY2026 "The trial is expected to enroll approximately 300 patients, with topline data expected by year end 2026." exhibit
Q2 FY2026 "Additionally, NewAmsterdam expects to initiate a new clinical trial evaluating obicetrapib for the prevention of early Alzheimer’s disease in 2026." exhibit
Q2 FY2026 "By 2050 more than 184 million U.S. adults are expected to be affected by CVD and hypertension, including 27 million with coronary heart disease and 19 million with stroke." exhibit
Q2 FY2026 "All statements that are not historical facts are hereby identified as forwarding-looking statements for this purposes and include, among others, statements relating to: the Company’s intention to conduct the PREVAIL interim analysis and its expectations regarding the timing of the interim analysis and when the result of the interim analysis may be announced; expectations regarding the timing of potential approval decisions from the European Commission for obicetrapib and the FDC of obicetrapib plus ezetimibe; the Company’s expectations for total enrollment figures for and topline data from the" exhibit
Q1 FY2026 "NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results – Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed ‑ dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Completed enrollment in REMBRANDT; Topline data from RUBENS Phase 3 expected by year-end 2026 – – Presented new analyses of Phase 3 BROOKLYN and BROADWAY studies at the American Co" exhibit
Q1 FY2026 "“We are excited following an initial blinded review of PREVAIL data after the two-year anniversary of enrollment completion — which showed a Year 1 overall MACE event rate consistent with BROADWAY and a Year 1-to-Year 2 overall MACE event rate lower than expected — and we have decided to conduct an interim analysis in the fourth quarter of 2026." exhibit
Q1 FY2026 "We are optimistic about the interim analysis and expect to report the result of the analysis in the first quarter of 2027." exhibit
Q1 FY2026 "Should the trial not stop for efficacy at that time, we anticipate completion by the end of 2027." exhibit
Q1 FY2026 "The trial is expected to enroll approximately 300 patients, with topline data expected by year end 2026." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/NAMS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/NAMS

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

NAMS earnings date badge

HTML

<a href="https://veritasdata.dev/company/NAMS/"><img src="https://veritasdata.dev/embed/NAMS.svg" alt="NAMS earnings date" width="240" height="56"></a>

Markdown

[![NAMS earnings date](https://veritasdata.dev/embed/NAMS.svg)](https://veritasdata.dev/company/NAMS/)

Script

<script async src="https://veritasdata.dev/embed/NAMS.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/NAMS"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.